Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma: Results of a phase 2 trial (SARC 005)

Between 30% and 50% of women who have high-grade uterine leiomyosarcoma (uLMS) limited to the uterus at diagnosis remain progression-free at 2 years. Adjuvant pelvic radiation does not improve outcome. The objective of the current study was to determine the 2-year and 3-year progression-free surviva...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2013-04, Vol.119 (8), p.1555-1561
Main Authors: Hensley, Martee L., Wathen, J. Kyle, Maki, Robert G., Araujo, Dejka M., Sutton, Gregory, Priebat, Dennis A., George, Suzanne, Soslow, Robert A., Baker, Laurence H.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy, Adjuvant
Cohort Studies
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Dermatology
Disease-Free Survival
Docetaxel
Doxorubicin - administration & dosage
Female
Gemcitabine
Humans
Leiomyosarcoma - drug therapy
Leiomyosarcoma - pathology
Medical sciences
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local - pathology
Prospective Studies
Taxoids - administration & dosage
Treatment Outcome
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Uterine Neoplasms - drug therapy
Uterine Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!